RxDoctor Payments Data

Luis Torregrosa, MD

Rheumatology · Dearborn, MINPI 1891765608

Payments from drug & device makers

$2,487in general payments, 2019–2025

Across 29 payments — averaging $85.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$627
  • Johnson & Johnson$356
  • Amgen$351
  • AbbVie$337
  • Janssen Scientific Affairs, LLC$241
  • AstraZeneca$134
  • plus $443 from 7 others

What the payments were for

  • Consulting fees$402%
  • Food & beverage$2,20889%
  • Education$23910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,487 in reported general payments places this provider in the 45th percentile of 195 rheumatology providers in Michigan.

See all rheumatology providers in Michigan

Medicare billing

Part B allowed, 2024
$6,056
Medicare patients
60
Services billed
64

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab14$163,837
Enbrel SureclickEtanercept23$160,410
Humira(Cf) PenAdalimumab13$89,850
SimponiGolimumab12$74,819
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen306$6,914
MethotrexateMethotrexate Sodium161$5,974
Duloxetine Hcl196$4,576
Pregabalin174$4,209
Mycophenolate Mofetil21$4,094
Gabapentin218$4,028
Hydroxychloroquine Sulfate73$3,064
Amitriptyline Hcl151$2,339
Leflunomide29$1,767
Azathioprine21$1,765
Prednisone166$1,749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSimponi$356$74,81912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 195 rheumatology providers in Michigan.

Other rheumatology in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →